2013 Fiscal Year Final Research Report
Pathogenesis and new drug targets in Myeloid cancer stem cells
| Project/Area Number |
24890177
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
SHIDE KOTARO 宮崎大学, 医学部, 助教 (20468028)
|
|---|
| Project Period (FY) |
2012-08-31 – 2014-03-31
|
| Keywords | 骨髄系腫瘍 / エピゲノム異常 |
|---|
| Research Abstract |
Role of TET2 mutations that occur commonly in abnormal hematopoietic stem cells of the myeloid tumors is unclear.
By analyzing TET2 deficient mice, we revealed what changes are occurred in the hematopoietic progenitor cells in which TET2 function is reduced . Application of the result to development of novel therapies for myeloid tumors is expected.
In addition, by using the JAK2V617F transgenic mice and TET2 deficient mice, we revealed that co-existence of TET2 mutations affect "severity of disease" and "enhancement of the onset ability" of JAK2V617F transgenic mice.
|
